Biomega's
research, conducted at New York University School of Medicine,
cuts across departments involving a number of School of Medicine
professionals. This cross fertilization of specialties is important
to the development of CIF™ and CIF™ Related Peptides, as they
must pass through numerous steps in the development process. The
professionals at NYU are at the leading edge of cancer research
and treatments.
To
accomplish its scientific/medical goals, Biomega has assembled
a Scientific Advisory Board to offer counsel in the development
of CIF.
The
Scientific Advisory Board is composed of some of the most respected
scientists in their particular areas of research.
To
accomplish its scientific/medical goals, Biomega has assembled
a Scientific Advisory Board to offer counsel in the development
of CIF.
The
membership of this Board includes:
-
Dr. Mina J. Bissell, member of the American Academy
of Arts and Sciences; Director, Life Sciences Division, Comparative
Biochemistry, UC Berkeley, the Ernest Orlando Lawrence Berkeley
National Laboratory, Berkeley, CA
-
Dr. Meenhard Herlyn, Professor and Chair of the Molecular
and Cellular Oncogenesis Program at The Wistar Institute;
Professor of Dermatology and Professor of Pathology and Laboratory
Medicine at the University of Pennsylvania School of Medicine,
Philadelphia, PA
-
Dr. David A. Fishman, Professor/Director, Gynecologic
Oncology, Cancer Prevention and Early Detection, NYU Cancer
Institute, New York, NY
-
Dr. Jay Fleischman, specialist in Retinal and Vitreous
Diseases and Surgery, Clinical Associate Professor of Ophthalmology,
Albert Einstein College of Medicine, Bronx, NY
-
Dr. George Lipkin, Professor of Dermatology; Director
of the Berger Foundation for Cancer Research; Director of
Melanoma Research Laboratory, NYUSM, New York, NY
-
Dr. Martin J. Rosenberg, Assistant Professor of Research,
Department of Dermatology, NYUSM, New York, NY.
CIF has been shown to
- Reverse the malignant phenotype of cancer
cells
- Restore normal growth control to cancer
cells in vitro. Cancer cells reacquire the three most
important characteristics of normal cells grown in culture
- Anchorage dependent growth
- Serum dependent growth
- Density dependent growth (contact
inhibition of growth)
- Inhibit metastasis
- Inhibit angiogenesis
- Cause permanent regression of cancer in
animal experiments
It does this through the
- Restoration of surface antigens to the
cancer cell making these cells susceptible to recognition and
destruction by both the humoral and cellular arm of the immune
system
- Restoration of the integrity of the actin
cytoskeleton; important in cell to cell signalling and in the
inhibition of metastasis
- Prevention of the release of VEGF from
cancer cells and the blocking of the angiogenic effect of bFGF
on blood vessels. (VEGF and bFGF are important angiogenic agents
that play a normal function in the body but whose presence are
also required for the abnormal growth of cancer and cells.)
- Inhibition of cell proliferation
- Induction of growth arrest at the physiologic
G1 check point in the cell cycle
- Decreased chemotaxis to laminin
- Decreased ICAM-I expression
And with no evidence of toxicity.
Biomega scientists believe that many, but
not all, of these physiologic effects are caused by CIF's interaction
with the mTOR Pathway, a highly conserved cell growth regulating
pathway found in species ranging from the fruit fly to humans.
mTOR regulates cell growth based on the levels of nutrients reaching
the cell, among other factors.
To
learn more, please contact:
Biomega Laboratories, Inc.
In
Care of: Richard D. Glaser, Ph.D.
NYC Phone:
(212) 307-4386 | CT Phone: (203)
838-6918 | Mobile
Phone: (917) 975-8400
Email: rdglaser@earthlink.net.
|
|
